We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Recommends Additional Studies for High-Risk Drugs
EMEA Recommends Additional Studies for High-Risk Drugs
April 12, 2007
Sponsors wishing to test high-risk new drugs for the first time on human subjects are advised to undertake additional preliminary studies in some circumstances, under a new draft guideline from the European Medicines Agency (EMEA).
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor